SISCAPA Assay Technologies

SISCAPA Assay Technologies, founded in 2004, has developed a robust protein quantification platform that merges mass spectrometry with immunoaffinity enrichment to solve challenging measurement problems in proteomics. The company operates primarily as a service and platform provider, offering assay development and analytical services to pharma and diagnostic partners for applications including therapeutic drug monitoring, target engagement, and biomarker analysis. Its SISCAPA technology addresses key industry pain points like assay interference, limited multiplexing, and the quantification of difficult targets such as transmembrane proteins and antibody-drug conjugates. The recent partnership with Biognosys aims to scale and regulate its assay offerings for broader adoption.

SISCAPA® (Stable Isotope Standards and Capture by Anti-Peptide Antibodies) technology combines immunoaffinity enrichment of target peptides with mass spectrometry (LC-MS/MS) for highly specific, sensitive, and multiplexable quantification of proteins in complex biological samples.

SISCAPA competes with traditional ligand-binding assay (LBA) providers and other proteomics platforms like Olink (proximity extension assays) and multiplex immunoassay vendors. Its key differentiation is the unique combination of MS specificity with antibody enrichment, particularly for challenging targets. The partnership with Biognosys also positions it against large CROs with internal MS capabilities.